Form 4: Erasca CFO Boosts Stake with Stock Purchase, Option Grant

Erasca's CFO and CBO, David M. Chacko, acquired additional common stock and received a significant stock option grant, increasing his beneficial ownership.

Summary

• David M. Chacko, CFO and CBO of Erasca, Inc. (ERAS), reported changes in his beneficial ownership.
• On December 15, 2025, Chacko purchased 17,793 shares of common stock at a price of $1.1943 per share through the company's 2021 Employee Stock Purchase Plan.
• Following this transaction, Chacko directly beneficially owns 279,980 shares of common stock.
• On January 29, 2026, Chacko was granted 640,000 stock options with an exercise price of $10.31 per share.
• These options begin vesting monthly on the 29th day of each month (or the last day of February), starting in February 2026, over a 48-month period, contingent on his continuous service.
• The stock options have an expiration date of January 29, 2036.
• Following the option grant, Chacko directly beneficially owns 640,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as increased insider ownership and a significant long-term incentive grant typically reflect management's confidence in the company's future performance and strategic direction.

Positives

• Increased insider ownership signals management's confidence in the company's future prospects.
• The significant stock option grant provides a long-term incentive for the CFO to drive shareholder value.

Future Outlook

The vesting schedule for the granted stock options, commencing in February 2026 and continuing monthly for 48 months, indicates a long-term commitment from the CFO to the company's performance and future growth, subject to continuous service.

Industry Context

StockSavvy.ai notes that insider transactions, such as stock purchases and option grants, are common mechanisms for aligning management's interests with those of shareholders. These actions often reflect management's belief in the company's intrinsic value and future potential within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• The filing does not provide sufficient context or data to directly compare the specific transaction details (e.g., option grant size relative to peer CFOs, ESPP participation rates) to industry benchmarks or comparable companies without external data.

Stakeholder Impact

• Shareholders may interpret the CFO's increased stake and long-term option grant as a positive indicator of management's commitment and belief in the company's future value, potentially boosting investor confidence.

Next Steps

• Monthly vesting of the 640,000 stock options will commence in February 2026, continuing for 48 months, subject to David M. Chacko's continuous service.

Key Dates

Recommendation

The insider purchase and significant option grant by a key executive like the CFO suggest strong internal confidence in Erasca's future. While this is a positive signal, it is a single data point and does not provide a comprehensive view of the company's financial health or strategic position to warrant a 'buy' without further analysis. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive insider sentiment while awaiting broader financial disclosures.

Keywords

Erasca, ERAS, David M. Chacko, CFO, CBO, Insider Trading, Form 4, Stock Purchase, Stock Option Grant, Employee Stock Purchase Plan, Beneficial Ownership